JP Patent

JP7584426B2 — 改善された組織特異性を有する前立腺特異的膜抗原（ｐｓｍａ）リガンド

Assigned to ルプレヒト－カールス－ウニベルジテート ハイデルベルク · Expires 2024-11-15 · 2y expired

What this patent protects

Patent listed against lutetium-lu-177-vipivotide-tetraxetan.

Drugs covered by this patent

Patent Metadata

Patent number
JP7584426B2
Jurisdiction
JP
Classification
—
Expires
2024-11-15
Drug substance claim
No
Drug product claim
No
Assignee
ルプレヒト－カールス－ウニベルジテート ハイデルベルク
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.